

PHARMACY COVERAGE GUIDELINE

YORVIPATH® (palopegteriparatide) Generic Equivalent (if available)

This Pharmacy Coverage Guideline (PCG):

- Provides information about the reasons, basis, and information sources we use for coverage decisions
- Is not an opinion that a drug (collectively “Service”) is clinically appropriate or inappropriate for a patient
- Is not a substitute for a provider’s judgment (Provider and patient are responsible for all decisions about appropriateness of care)
- Is subject to all provisions e.g. (benefit coverage, limits, and exclusions) in the member’s benefit plan; and
- Is subject to change as new information becomes available.

Scope

- This PCG applies to Commercial and Marketplace plans
- This PCG does not apply to the Federal Employee Program, Medicare Advantage, Medicaid or members of out-of-state Blue Cross and/or Blue Shield Plans

Instructions & Guidance

- To determine whether a member is eligible for the Service, read the entire PCG.
 - This PCG is used for FDA approved indications including, but not limited to, a diagnosis and/or treatment with dosing, frequency, and duration.
 - Use of a drug outside the FDA approved guidelines, refer to the appropriate Off-Label Use policy.
 - The “Criteria” section outlines the factors and information we use to decide if the Service is medically necessary as defined in the Member’s benefit plan.
 - The “Description” section describes the Service.
 - The “Definition” section defines certain words, terms or items within the policy and may include tables and charts.
 - The “Resources” section lists the information and materials we considered in developing this PCG
 - **We do not accept patient use of samples as evidence of an initial course of treatment, justification for continuation of therapy, or evidence of adequate trial and failure.**
 - Information about medications that require prior authorization is available at www.azblue.com/pharmacy. You must fully complete the [request form](#) and provide chart notes, lab workup and any other supporting documentation. The prescribing provider must sign the form. Fax the form to BCBSAZ Pharmacy Management at (602) 864-3126 or email it to Pharmacyprecert@azblue.com.
-

Criteria:

- **Criteria for initial therapy:** Yorvipath (palopegteriparatide) and/or generic equivalent (if available) is considered **medically necessary** and will be approved when **ALL** the following criteria are met:
 1. Prescriber is a physician specializing in the patient’s diagnosis or is in consultation with an Endocrinologist or Nephrologist
 2. Individual is 18 years of age or older
 3. Individual has a confirmed diagnosis of **hypoparathyroidism** that is not controlled with use of calcium supplements and active forms of vitamin D

PHARMACY COVERAGE GUIDELINE

YORVIPATH® (palopegteriparatide) Generic Equivalent (if available)

4. **If available:** Individual has failure after adequate trial, contraindication per FDA label, intolerance, or is not a candidate for a **generic equivalent** [Note: Failure, contraindication or intolerance to the generic should be reported to the FDA] ([see Definitions section](#))
5. Individual has completed **ALL** the following **baseline tests** before initiation of treatment and will have continued monitoring as clinically appropriate:
 - a. 25-hydroxyvitamin D is between 20 and 80 ng/mL
 - b. Serum albumin-corrected calcium is between 7.8 and 10.6 mg/dL or an ionized serum calcium greater than or equal to 4.4 mg/dL while on calcium and active vitamin D treatment
 - c. Low serum parathyroid level (less than 20 pg/mL) for at least 26 weeks
 - d. Serum magnesium concentration is greater than or equal to 1.3 mg/dL and below the upper limit of normal of the reference range
 - e. 24-hour urinary calcium is greater than 125 mg/24h
6. Yorvipath (palopegteriparatide) is **not** being used in an individual with acute post-surgical hypoparathyroidism
7. Individual does **not** have risk factors for osteosarcoma ([see Definitions section](#))
8. There is no evidence of hypocalcemia or hypercalcemia
9. Yorvipath (palopegteriparatide) is **not** being used concurrently with teriparatide (generic or brands Forteo, Bonsity), or Tymlos (abaloparatide), or denosumab products

Initial approval duration: 6 months

- **Criteria for continuation of coverage (renewal request):** Yorvipath (palopegteriparatide) and/or generic equivalent (if available) is considered **medically necessary** and will be approved when **ALL** the following criteria are met (**samples are not considered for continuation of therapy**):
1. Individual continues to be seen by a physician specializing in the patient's diagnosis or is in consultation with an Endocrinologist or Nephrologist
 2. Individual has documentation of positive clinical response to therapy defined as the following:
 - a. Achieves and maintains **TWO** of the following:
 - i. Total serum calcium (albumin-corrected) is within the lower half of the normal range (i.e., between 8.3-10.6 mg/dL) without the need for active forms of vitamin D (ex., calcitriol) or therapeutic calcium doses (ex., elemental calcium greater than 600 mg per day). Calcium supplementation sufficient to meet the individual's daily dietary requirements may be continued
 - ii. At least a 50% reduction from baseline in the dose of active vitamin D
 - iii. At least a 50% reduction from baseline in the dose of therapeutic oral calcium supplementation
 - b. No evidence of disease progression
 3. Individual has been adherent with the medication

ORIGINAL EFFECTIVE DATE: 11/21/2024 | ARCHIVE DATE: | LAST REVIEW DATE: 11/20/2025 | LAST CRITERIA REVISION DATE: 11/20/2025

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.

PHARMACY COVERAGE GUIDELINE

YORVIPATH® (palopegteriparatide) Generic Equivalent (if available)

4. Requested dose is not greater than 30 mcg once daily given as one injection
5. **If available:** Individual has failure after adequate trial, contraindication per FDA label, intolerance, or is not a candidate for a **generic equivalent** [Note: Failure, contraindication or intolerance to the generic should be reported to the FDA] ([see Definitions section](#))
6. Individual does **not** have risk factors for osteosarcoma ([see Definitions section](#))
7. There is no evidence of hypocalcemia or hypercalcemia
8. Yorvipath (palopegteriparatide) is **not** being used concurrently with teriparatide (generic or brands Forteo, Bonsity), or Tymlos (abaloparatide), or denosumab products
9. Individual has not developed any significant unacceptable adverse drug effects that may exclude continued use such as:
 - a. Severe hypercalcemia
 - b. Severe hypocalcemia
 - c. Hypercalciuria (urine calcium > 300mg/24 hours or > 7.5 mmol/24 hours)
 - d. Osteosarcoma

Renewal duration: 12 months

- Criteria for a request for non-FDA use or indication, treatment with dosing, frequency, or duration outside the FDA-approved dosing, frequency, and duration, refer to one of the following Pharmacy Coverage Guideline:

1. **Off-Label Use of Non-Cancer Medications**
 2. **Off-Label Use of Cancer Medications**
-

Description:

Yorvipath (palopegteriparatide) is a parathyroid hormone analog (PTH (1-34)) indicated for the treatment of hypoparathyroidism in adults. It has not been studied for acute post-surgical hypoparathyroidism. The titration dosing scheme only evaluated in adults who first achieved an albumin-corrected serum calcium of at least 7.8 mg/dL using calcium and active vitamin D treatment. The normal range for albumin-corrected serum calcium is 8.3 to 10.6 mg/dL. Palopegteriparatide is a prodrug of teriparatide (PTH (1-34)) consisting of PTH (1-34) transiently conjugated to an inert carrier via a proprietary TransCon Linker. The carrier is a methoxypolyethylene glycol (mPEG) moiety.

The maximum dose of Yorvipath (palopegteriparatide) is 30 mcg subcutaneously once daily using once injection. Use of two injections to achieve a once daily dosage increases the variability of the total delivered dose which may lead to hypocalcemia or hypercalcemia. Individualize dosage based on serum calcium.

PHARMACY COVERAGE GUIDELINE

YORVIPATH® (palopegteriparatide) Generic Equivalent (if available)

Parathyroid hormone raises serum calcium by increasing renal tubular calcium reabsorption, increasing intestinal calcium absorption (by converting 25-OH vitamin D to 1, 25-OH₂ vitamin D) and by increasing bone turnover which releases calcium into the circulation.

Definitions:

U.S. Food and Drug Administration (FDA) MedWatch Forms for FDA Safety Reporting
[MedWatch Forms for FDA Safety Reporting | FDA](#)

Adult: Age 18 years and older

Increased risk of osteosarcoma patients with:

- Open epiphyses
- Metabolic bone diseases including Paget's disease or unexplained elevations of alkaline phosphatase
- Bone metastases or history of skeletal malignancies
- Prior external beam or implant radiation therapy involving the skeleton
- Hereditary disorders predisposing to osteosarcoma.

Albumin-corrected serum calcium [cCa, mg/dL]:

Individual's serum calcium (mg/dL) + 0.8 (4.0 – individual's serum albumin [g/dL])

25 hydroxy-vitamin D levels:

20-50 ng/mL (50-125 nmol/L)

Resources:

Yorvipath (palopegteriparatide) product information, revised by Ascendis Pharma, Inc. 08-2024. Available at DailyMed
<http://dailymed.nlm.nih.gov>. Accessed June 27, 2025.

Glotzman D. Hypoparathyroidism. In: UpToDate, Rosen CJ, Wolfsdorf JI, Mulder JE (Eds), UpToDate, Waltham MA.: UpToDate Inc. Available at <http://uptodate.com>. Literature current through August 2025. Topic last updated March 11, 2025. Accessed October 01, 2025.

Glotzman D. Treatment of hypocalcemia. In: UpToDate, Rosen CJ, Mulder JE (Eds), UpToDate, Waltham MA.: UpToDate Inc. Available at <http://uptodate.com>. Literature current through August 2025. Topic last updated June 16, 2024. Accessed October 01, 2025.

Dawson-Hughes B. Vitamin D deficiency in adults: Definition, clinical manifestations, and treatment. In: UpToDate, Rosen CJ, Rubinow K (Eds), UpToDate, Waltham MA.: UpToDate Inc. Available at <http://uptodate.com>. Literature current through August 2025. Topic last updated May 21, 2025. Accessed October 01, 2025.

Mannstadt M. Parathyroid hormone secretion and action. In: UpToDate, Rosen CJ, Rubinow K (Eds), UpToDate, Waltham MA.: UpToDate Inc. Available at <http://uptodate.com>. Literature current through August 2025. Topic last updated February 25, 2025. Accessed October 01, 2025.



An Independent Licensee of the Blue Cross Blue Shield Association

PHARMACY COVERAGE GUIDELINE

YORVIPATH® (palopegteriparatide) Generic Equivalent (if available)

Khan AA, Rubin MR, Schwarz P, et al.: Efficacy and Safety of Parathyroid Hormone Replacement With TransCon PTH in Hypoparathyroidism: 26-Week Results From the Phase 3 PaTHway Trial. *J Bone Miner Res.* 2023 Jan; 38(1): 14–25. Re-evaluated October 01, 2025.

ClinicalTrials.gov Bethesda (MD): National Library of Medicine (US). Identifier NCT04701203: PaTHway TRIAL: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial, With an Open-Label Extension, Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Subcutaneously Daily in Adults With Hypoparathyroidism. Available from: <http://clinicaltrials.gov>. Last update posted January 31, 2024. Last verified January 2024. Accessed October 15, 2024. Re-evaluated October 02, 2025.

ORIGINAL EFFECTIVE DATE: 11/21/2024 | ARCHIVE DATE: | LAST REVIEW DATE: 11/20/2025 | LAST CRITERIA REVISION DATE: 11/20/2025

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.